Brought to you by 
AZ takes 50% cut of Amylin diabetes portfolio through partnership with BMS
30 Jan 2023
Executive Summary
In a transaction that expands their diabetes partnership, Bristol-Myers Squibb Co. is granting AstraZeneca PLC a 50% share of the assets that BMS gains once it completes its concurrently announced $6.8bn acquisition of Amylin Pharmaceuticals Inc.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ takes 50% cut of Amylin diabetes portfolio through partnership with BMS
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice